Clinical Trial Detail

NCT ID NCT02289144
Title Ceritinib (LDK378) in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors University of Texas Southwestern Medical Center
Indications

thyroid cancer

Therapies

Ceritinib

Age Groups: adult

Additional content available in CKB BOOST